These findings are consistent with the clinical situation where JAK2-mutations indicate an increased risk for thromboembolic events per se compared to non-JAK-mutated MPN cases [174] and administration of salicylic acid is routinely used to prevent thrombotic complications [175]. Here, JAK2 is linked to myeloproliferative disorder.